Evidence map›Paper›PMID 41986654›Full record

ArticleOncogene2026

Correction: Steroid receptor coactivator-1 facilitates METTL3-mediated m6A modification by coactivating NF-κB and promotes the malignant progression of glioblastoma.

Liang Liu, Rui Wang, Ke Cheng, Chunmei Bai, Yuke Ji, Yifei Zhang, Haoran Yang, Miaomiao Gong, Fang Xie, Yongshun Zhao and 2 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Liang Liu *The Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Rui Wang *The Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Ke Cheng *The Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.ORCID http://orcid.org/0009-0003-7150-2120
Chunmei BaiThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Yuke JiThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Yifei ZhangThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Haoran YangThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Miaomiao GongThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.ORCID http://orcid.org/0009-0005-2021-3817
Fang XieThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
Yongshun ZhaoThe First Affiliated Hospital, Dalian Medical University, Dalian, China. zhaoyongshun_2005@aliyun.com.
Jinjin PanThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China. panjinjin1987@163.com.
Yuhui YuanThe Second Affiliated Hospital, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China. yuhuiyuan@hotmail.com.ORCID http://orcid.org/0000-0002-7109-6703

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41986654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.